ABTNYSEhealth care

Abbott Laboratories

$92.11下跌-1.82 (-1.94%)

研究复核截至: 2026年7月12日上午12:00 [UTC]

研究概览

Abbott Laboratories operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

開盤: 93.95
最高: 94.00
最低: 91.64
市值: 1604.38億
本益比: 25.80
52 週高點: --
股息: 2.680%
季度股利金額: --

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The base case remains conditional on nutrition weakness staying manageable.
多头情景: Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.
空头情景: Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

关键催化剂

Medical devices growth
Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine.
Oncology diagnostics expansion
The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics.
Established pharmaceuticals growth
Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

主要风险

Nutrition weakness
Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.
Exact Sciences integration
The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized.
Infant-formula litigation
Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

估值解读

Sustained medical-device growth and successful oncology-diagnostics expansion can support a diversified health-care quality premium.
Nutrition weakness and the scale of Exact Sciences integration warrant a discount until acquired growth and financial synergies become visible.